

# Diagnosis of axillary lymph node status in primary breast cancer without a surgical procedure - a human factors validation test

<b>Submission date</b> 10/11/2024	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 15/11/2024	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 28/05/2026	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

NILS (Non-invasive Lymph node Staging) is a web-based software that uses artificial intelligence to predict sentinel lymph node status in women who are planned for primary surgery due to breast cancer and are clinically axillary lymph node-negative. NILS is not yet CE-marked and is not available on the market. Previously, formative usability engineering evaluation has been performed with NILS. This study is a summative evaluation study in preparation of market access. The main aim is to present evidence that the NILS interface is considered safe. The study will be conducted according to the standard IEC 62366-1:2015. For the purpose of this pre-market study, a study under simulated conditions will be performed.

### Who can participate

This study is for licensed medical physicians specialized in general surgery or oncology (including medical and radiation oncologists).

### What does the study involve?

During the simulated-use testing, the test participant will be given the opportunity to use the web-calculator independently and as naturally as possible in their own work environment, without unnecessary interference from the test leader or observer. The test participants will be asked to perform five scenarios, with five different simulated patient cases. After calculating each case using NILS, the test participants will fill in the appropriate clinical pathway based on the NILS result and other available information. The participants' interaction with the interface will be controlled by a test leader and an observer who will follow a predefined protocol. All tasks have been identified (risk management procedure according to ISO 14971) and critical tasks specified.

The study will take place in three different health care regions and 4 different hospitals in Sweden. The conditions under which the simulated-use testing will be conducted will be sufficiently realistic so that the results of the testing are generalizable to actual intended use.

Therefore, fabricated, but realistic, patient cases will be used for the testing. In addition, cases are created to ensure that all critical tasks are performed during the test and that the test conditions are sufficiently realistic to represent actual conditions of use.

After each case the test participant will be asked to fill in the clinical pathway that they find most appropriate based on the information they have received and the NILS calculation. Several pathways can be appropriate: "Consider omitting SLNB", "Consider performing SLNB", "Definitely perform SLNB", and "NILS cannot assist in making the clinical decision". The test participants will following be asked to fill in a validated questionnaire about their experience of the device. Interview questions will be asked after the use of the interface if any tasks were incorrectly or close to incorrectly executed.

What are the possible benefits and risks of participating?

The participants will receive a small symbolic compensation for the participation. No risks of participating have been identified.

Where is the study run from?

Lunds University Cancer Center in cooperation with the South Swedish Health Care Region.

When is the study starting and how long is it expected to run for?

November 2024 to June 2025

Who is funding the study?

1. The Governmental Funding of Clinical Research within the National Health Services (Sweden).
2. The Swedish Cancer Society (Sweden).
3. Lunds University (Sweden).
4. Region Skåne/South Swedish Health Care Region (Sweden)
5. The Swedish Research Council (Sweden)
6. The Erling Persson Foundation (Sweden).

Funding resources had no role in the study design, data collection, analyses, data interpretation, writing of the manuscript, or the decision to submit the manuscript for publication.

Who is the main contact?

MD Anna Allfelt, [anna.allfelt@med.lu.se](mailto:anna.allfelt@med.lu.se)

MD, PhD Ida Skarping, [ida.skarping@med.lu.se](mailto:ida.skarping@med.lu.se)

## Contact information

### Type(s)

Principal investigator

### Contact name

Prof Lisa Rydén

### ORCID ID

<https://orcid.org/0000-0001-7515-3130>

### Contact details

Bröst och melanommottagning, SUS  
Tora Kjellgrens gata 27

Malmö  
Sweden  
205 02  
+46 (0)46176241  
lisa.ryden@med.lu.se

**Type(s)**  
Scientific

**Contact name**  
Dr Ida Skarping

**ORCID ID**  
<https://orcid.org/0000-0002-1265-8649>

**Contact details**  
Klinisk fysiologi och nuklearmedicin, SUS  
Entrégatan 7  
Lund  
Sweden  
221 85  
+46 (0)46177309  
ida.skarping@med.lu.se

**Type(s)**  
Public

**Contact name**  
Mrs Anna Allfelt

**ORCID ID**  
<https://orcid.org/0009-0002-7889-9821>

**Contact details**  
Bröst och melanommottagning, SUS  
Tora Kjellgrens gata 27  
Malmö  
Sweden  
205 02  
+46 (0)40335357  
anna.allfelt@med.lu.se

## **Additional identifiers**

## **Study information**

**Scientific Title**  
Human factors validation study of an artificial neural networkbased preoperative decisionsupport tool for noninvasive lymph node staging (NILS) in women with primary breast cancer

## **Study objectives**

From a usability point-of-view evaluating the final product with intended-use testing, the hypothesis is to present evidence that the interface for NILS is considered safe.

## **Ethics approval required**

Ethics approval not required

## **Ethics approval(s)**

This usability study is not a clinical study, and it does not require an ethical approval from the Swedish Ethical Review Authority. The usability study is approved by the Head of Research in Region Skåne regarding the intended conduction of the study and Region Skåne is thus the legal authority for the study.

## **Study design**

Pre-market human factors validation test under simulated conditions.

## **Primary study design**

Observational

## **Study type(s)**

Other

## **Health condition(s) or problem(s) studied**

Pre-market human factor validation test with intended (actual) users.

## **Interventions**

The test participants will be greeted by the test leader and be provided a written instruction for use manual. The test participants will be presented with five simulated cases and are expected to fill in the patient information correctly and press calculate. The test participants are then expected to interpret the result of the calculation correctly and consider the calculated results of probability of a benign axillary nodal status together with other sources of information when subsequently determining the most appropriate clinical pathway for the patient. The hypothetical treatment decision per se will not be evaluated. This will be done five times covering all the cases. The test participants will following be asked to fill in a validated questionnaire about their experience of the device. Lastly a short oral interview will take place if indicated. The total time required per test-participant is approximately 45-60 min. No follow-up is planned.

## **Intervention Type**

Other

## **Primary outcome(s)**

1. Frequency of observed outcome and result during the test, analysis per task. Observed outcome is defined as correct use, close call, use difficulty, and use error. Result is defined as passed or failed.
2. Frequency of passed critical tasks per scenario.
3. Frequency of observed outcome and result during the test, analysis per task description in association with potential harm (false estimated indication of benign sentinel lymph node). Observed outcome is defined as correct use, close call, use difficulty, and use error. Result is defined as passed or failed.

4. Average point (median) on Likert scale 1-5 and 1-7: 1 “strongly disagree” to 5 respectively 7 “strongly agree” in validated questionnaire (Lewis J.R 2018 and 1995).
5. Review of all comments in validated questionnaire (Lewis J.R 2018 and 1995) and interview data with the purpose to detect potential safety and performance concerns.

Since NILS has not yet been released to the market and has had limited contact with the intended users, it is likely that some usability issues may be detected. However, a large amount of user errors is not acceptable. Therefore, the team has set the acceptance criteria to 90%.

Each test protocol interview data will be reviewed and all comments with potential safety and performance concerns will be analyzed to assess any required changes in design. In case any significant change of the NILS web page will be needed, the change will be re-assessed using a new scenario with the purpose to re-evaluate the potential concern. The qualitative evaluation will be acceptable when no potential safety and performance concerns remain to be analyzed or addressed.

### **Key secondary outcome(s)**

There are no secondary outcome measures

### **Completion date**

30/06/2025

## **Eligibility**

### **Key inclusion criteria**

1. Intended users - licensed medical physicians specialized in general surgery or oncology (including medical and radiation oncologists)
2. >18 years
3. Both sexes

### **Participant type(s)**

Health professional

### **Healthy volunteers allowed**

No

### **Age group**

Mixed

### **Lower age limit**

18 years

### **Upper age limit**

65 years

### **Sex**

All

### **Total final enrolment**

0

**Key exclusion criteria**

1. Any former contact with the device

**Date of first enrolment**

12/09/2024

**Date of final enrolment**

31/12/2024

**Locations****Countries of recruitment**

Sweden

**Study participating centre****Skånes universitetssjukhus Malmö**

Inga Marie Nilssons gata 47

Malmö

Sweden

214 28

**Study participating centre****Skånes universitetssjukhus Lund**

Entrégatan 7

Lund

Sweden

222 42

**Study participating centre****Centralsjukhuset Kristianstad**

J A Hedlunds väg 5

Kristianstad

Sweden

291 33

**Study participating centre****Blekingesjukhuset Karlskrona**

Lasarettsvägen

Karlskrona

Sweden

371 41

**Study participating centre**  
**Centrallasarettet Växjö**  
Strandvägen 8  
Växjö  
Sweden  
352 34

## Sponsor information

**Organisation**  
Region Skåne/South Swedish Health Care Region

## Funder(s)

**Funder type**  
Government

**Funder Name**  
The Governmental Funding of Clinical Research within the National Health Services Sweden

**Alternative Name(s)**  
Lund University, Universitas Lundensis, Universitas Gothorum Carolina, Royal Caroline Academy, Regia Academia Carolina, Lund University | Lund, Sweden | LU, Lunds universitet, LU

**Funding Body Type**  
Government organisation

**Funding Body Subtype**  
Universities (academic only)

**Location**  
Sweden

**Funder Name**  
The Swedish Cancer Society

**Funder Name**  
Lunds University

## Funder Name

Region Skåne/South Swedish Health Care Region

## Funder Name

The Swedish Research Council

## Funder Name

The Erling Persson Foundation

# Results and Publications

## Individual participant data (IPD) sharing plan

The dataset generated and analyzed during the current study will be available upon reasonable request from Anna Allfelt, [anna.allfelt@med.lu.se](mailto:anna.allfelt@med.lu.se)

## IPD sharing plan summary

Available on request

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		28/05/2026	28/05/2026	Yes	No
<a href="#">Other files</a>	Instructions for participants		15/11/2024	No	No
<a href="#">Other files</a>	Instructions for use		15/11/2024	No	No
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes